{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T01:49:00Z","timestamp":1790732940723,"version":"4.1.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T00:00:00Z","timestamp":1551225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"Gilead Science"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Tenofovir alafenamide produces lower plasma tenofovir and higher intracellular tenofovir diphosphate (DP) concentrations than tenofovir disoproxil fumarate but it is likely a victim of interactions with rifampicin. We aimed to investigate the pharmacokinetics of tenofovir alafenamide\/emtricitabine with rifampicin.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>Healthy volunteers received tenofovir alafenamide\/emtricitabine at 25\/200\u2009mg once daily, followed by tenofovir alafenamide\/emtricitabine + rifampicin daily followed by tenofovir disoproxil fumarate. Plasma tenofovir alafenamide, tenofovir, emtricitabine and intracellular tenofovir-DP and emtricitabine triphosphate pharmacokinetics and genetic polymorphisms were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Tenofovir alafenamide exposure decreased when tenofovir alafenamide\/emtricitabine\u205f+\u205frifampicin was used compared with tenofovir alafenamide\/emtricitabine [geometric mean ratio (GMR) (90% CI): 0.45 (0.33\u20130.60)]. Plasma tenofovir and intracellular tenofovir-DP concentrations decreased with rifampicin [GMR (90% CI): 0.46 (0.40\u20130.52) and 0.64 (0.54\u20130.75), respectively]. GMR (90% CI) of intracellular tenofovir-DP AUC0\u201324 for tenofovir alafenamide\/emtricitabine + rifampicin versus tenofovir disoproxil fumarate was 4.21 (2.98\u20135.95). Rifampicin did not affect emtricitabine pharmacokinetics. CYP3A4*22 rs35599367 was associated with higher plasma tenofovir alafenamide AUC0\u201324 at day 56.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Following tenofovir alafenamide\/emtricitabine administration with rifampicin, intracellular tenofovir-DP concentrations were still 4.21-fold higher than those achieved by tenofovir disoproxil fumarate, supporting further study during HIV\/TB co-infection.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jac\/dkz068","type":"journal-article","created":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T20:23:37Z","timestamp":1549052617000},"page":"1670-1678","source":"Crossref","is-referenced-by-count":62,"title":["Rifampicin effect on intracellular and plasma pharmacokinetics of tenofovir alafenamide"],"prefix":"10.1093","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6900-6086","authenticated-orcid":false,"given":"Maddalena","family":"Cerrone","sequence":"first","affiliation":[{"name":"St Stephen\u2019s AIDS Trust, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omamah","family":"Alfarisi","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Neary","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark A","family":"Marzinke","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa L","family":"Parsons","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Owen","sequence":"additional","affiliation":[{"name":"Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Maartens","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, University of Cape Town, Cape Town, South Africa"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anton","family":"Pozniak","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s AIDS Trust, Chelsea and Westminster Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Flexner","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, Baltimore, MD, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Boffito","sequence":"additional","affiliation":[{"name":"St Stephen\u2019s AIDS Trust, Chelsea and Westminster Hospital, London, UK"},{"name":"Imperial College London, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,2,27]]},"reference":[{"key":"2021061512505646700_dkz068-B1"},{"key":"2021061512505646700_dkz068-B2"},{"key":"2021061512505646700_dkz068-B3","volume-title":"Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach","year":"2016"},{"key":"2021061512505646700_dkz068-B4","year":"2017"},{"key":"2021061512505646700_dkz068-B5"},{"key":"2021061512505646700_dkz068-B6","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndrom"},{"key":"2021061512505646700_dkz068-B7","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1097\/QAI.0000000000000225","article-title":"Tenofovir alafenamide vs. tenofovir disoproxil fumarate in single tablet regimens for initial HIV-1 therapy: a randomized phase 2 study","volume":"67","author":"Sax","year":"2014","journal-title":"J Acquir Immune Defic Syndrom"},{"key":"2021061512505646700_dkz068-B8","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1097\/QAI.0000000000000618","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate in the first protease inhibitor-based single-tablet regimen for initial HIV-1 therapy: a randomized phase 2 study","volume":"69","author":"Mills","year":"2015","journal-title":"J Acquir Immune Defic Syndrom"},{"key":"2021061512505646700_dkz068-B9","doi-asserted-by":"crossref","first-page":"e5146.","DOI":"10.1097\/MD.0000000000005146","article-title":"The efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in antiretroviral regimens for HIV-1 therapy","volume":"95","author":"Wang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"2021061512505646700_dkz068-B10","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.1128\/AAC.00005-16","article-title":"Pharmacokinetics and safety of tenofovir alafenamide in HIV-uninfected subjects with severe renal impairment","volume":"60","author":"Custodio","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061512505646700_dkz068-B11","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1080\/15284336.2017.1291867","article-title":"Efficacy and safety of emtricitabine\/tenofovir alafenamide (FTC\/TAF) vs. emtricitabine\/tenofovir disoproxil fumarate (FTC\/TDF) as a backbone for treatment of HIV-1 infection in virologically suppressed adults: subgroup analysis by third agent of a randomized, double-blind, active controlled phase 3 trial","volume":"18","author":"Post","year":"2017","journal-title":"HIV Clin Trials"},{"key":"2021061512505646700_dkz068-B12","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061512505646700_dkz068-B13","first-page":"465","volume-title":"J Acquir Immune Defic Syndr","author":"Begley","year":"2018"},{"key":"2021061512505646700_dkz068-B14","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1021\/mp3002045","article-title":"Mechanism for effective lymphoid cell and tissue loading following oral administration of nucleotide prodrug GS-7340","volume":"10","author":"Babusis","year":"2013","journal-title":"Mol Pharm"},{"key":"2021061512505646700_dkz068-B15","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1124\/mol.108.045526","article-title":"Activation of 9-[(R)-2-[[(S)-[[(S)-1-(isopropoxycarbonyl)ethyl]amino] phenoxyphosphinyl]-methoxy]propyl]adenine (GS-7340) and other tenofovir phosphonoamidate prodrugs by human proteases","volume":"74","author":"Birkus","year":"2008","journal-title":"Mol Pharmacol"},{"key":"2021061512505646700_dkz068-B16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1172\/JCI6663","article-title":"The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin","volume":"104","author":"Greiner","year":"1999","journal-title":"J Clin Invest"},{"key":"2021061512505646700_dkz068-B17","doi-asserted-by":"crossref","first-page":"819","DOI":"10.2165\/00003088-200342090-00003","article-title":"Pharmacokinetic interactions with rifampicin: clinical relevance","volume":"42","author":"Niemi","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"2021061512505646700_dkz068-B18"},{"key":"2021061512505646700_dkz068-B19","volume-title":"Abstracts of the 16th European AIDS Conference (EACS)","author":"Custodio","year":"2017"},{"key":"2021061512505646700_dkz068-B20"},{"key":"2021061512505646700_dkz068-B21"},{"key":"2021061512505646700_dkz068-B22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1089\/aid.2015.0182","article-title":"Dose frequency ranging pharmacokinetic study of tenofovir-emtricitabine after directly observed dosing in healthy volunteers to establish adherence benchmarks (HPTN 066)","volume":"32","author":"Hendrix","year":"2016","journal-title":"AIDS Res Hum Retroviruses"},{"key":"2021061512505646700_dkz068-B23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.jpba.2018.02.011","article-title":"Validation and implementation of liquid chromatographic-mass spectrometric (LC\u2013MS) methods for the quantification of tenofovir prodrugs","volume":"152","author":"Hummert","year":"2018","journal-title":"J Pharm Biomed Anal"},{"key":"2021061512505646700_dkz068-B24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.jchromb.2006.05.043","article-title":"Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells","volume":"843","author":"King","year":"2006","journal-title":"J Chromatogr B Anal Technol Biomed Life Sci"},{"key":"2021061512505646700_dkz068-B25","first-page":"908","article-title":"Geometric means and measures of dispersion","volume":"35","author":"Kirkwood","year":"1979","journal-title":"Source: Biometrics"},{"key":"2021061512505646700_dkz068-B26","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/aje\/kwn359","article-title":"Hardy-Weinberg equilibrium testing of biological ascertainment for Mendelian randomization studies","volume":"169","author":"Rodriguez","year":"2009","journal-title":"Am J Epidemiol"},{"key":"2021061512505646700_dkz068-B27","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of human immunodeficiency virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res"},{"key":"2021061512505646700_dkz068-B28","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1128\/AAC.01834-15","article-title":"Intracellular activation of tenofovir alafenamide and the effect of viral and host protease inhibitors","volume":"60","author":"Birkus","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061512505646700_dkz068-B29","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1097\/COH.0000000000000376","article-title":"Compatibility of next-generation first-line antiretrovirals with rifampicin-based antituberculosis therapy in resource limited settings","volume":"12","author":"Maartens","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2021061512505646700_dkz068-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fphar.2016.00111","article-title":"Rifampin regulation of drug transporters gene expression and the association of microRNAs in human hepatocytes","volume":"7","author":"Benson","year":"2016","journal-title":"Front Pharmacol"},{"key":"2021061512505646700_dkz068-B31"},{"key":"2021061512505646700_dkz068-B32"},{"key":"2021061512505646700_dkz068-B33","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2131\/jts.38.349","article-title":"CYP3A4 intron 6 C&gt;T polymorphism (CYP3A4*22) is associated with reduced CYP3A4 protein level and function in human liver microsomes","volume":"38","author":"Okubo","year":"2013","journal-title":"J Toxicol Sci"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/6\/1670\/38646231\/jac_74_6_1670.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/74\/6\/1670\/38646231\/jac_74_6_1670.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,15]],"date-time":"2021-06-15T12:52:57Z","timestamp":1623761577000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/74\/6\/1670\/5366220"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,27]]},"references-count":33,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,2,27]]},"published-print":{"date-parts":[[2019,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkz068","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,6]]},"published":{"date-parts":[[2019,2,27]]}}}